Peer Reviewed Studies on Psilocybin.
Since 1997, when the first post-drug-war Psilocybin study was conducted by a team of researchers at the University of Zurich, interest in the substance by accredited & prestigious institutions has steadily increased.
Studies and early-phase clinical trials already concluded at John Hopkins University, The Multidisciplinary Association for Psychedelic Studies (MAPS), The Beckley Foundation, and New York University have shown promise for the safety and efficacy of psilocybin in treating a host of psychological conditions. Some of these conditions include depression, addiction, anxiety, OCD, PTSD, and eating disorders.
In the decades since the turn of the century public attitude has also positively shifted towards the unfettered and open-minded research of psilocybin. Now, in 2020, governing bodies are beginning to follow suit. The FDA (Federal Drug Administration) has designated psilocybin a breakthrough therapy for Major Depressive Disorder (MDD), a condition affecting over 300 million people worldwide.
Over a dozen accredited institutions, a few of which include Harvard, Stanford, Yale, The Usona Institute, The Heffter Institute, Johns Hopkins University, and the University of Toronto are in the process of clinical trials/studies to determine the potential of psilocybin as a therapeutic aid, and there is a mountain of anecdotal evidence that cannot be discounted.
Some of the Universities currently studying Psilocybin.
Some of the claims made regarding psilocybin and its capability to treat a variety of conditions on a long term basis, with low frequency of dosage, may seem exaggerated or outlandish. However they are backed by a body of credible research that is constantly expanding. We have curated a collection of the most relevant studies specific to Psilocybin below.